Harmony Biosciences reiterated 2026 WAKIX net revenue guidance of $1.0 bln to $1.04 bln.
The company expects BP-205 Phase 1 MAD data in Q4 2026 and Phase 1b data in early 2027.
Pitolisant GR NDA was accepted, with a target PDUFA date of April 1, 2027; Pitolisant HD topline data is expected in 2027.
What drove the revenue growth
Patient growth - The company said increased average patient numbers for WAKIX contributed to Q2 revenue growth.
Commercial expansion - The company said expansion of field sales, remote sales, reimbursement and patient outreach teams supported WAKIX growth.
Access improvements - The company said launch of an online portal and changes to the reimbursement support process enabled faster and higher success rates for patients securing WAKIX.
Analyst coverage and valuation
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell".
The average consensus recommendation for the pharmaceuticals peer group is "buy".
Wall Street's median 12-month price target for Harmony Biosciences Holdings Inc is $44.00, about 23.6% above its August 3 closing price of $35.60.
HRMY•
